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Abstract
The risk of radiation exposure, due to accidental or malicious release of ionizing radiation, is a major public health concern.
Biomarkers that can rapidly identify severely-irradiated individuals requiring prompt medical treatment in mass-casualty
incidents are urgently needed. Stable blood or plasma-based biomarkers are attractive because of the ease for sample
collection. We tested the hypothesis that plasma miRNA expression profiles can accurately reflect prior radiation exposure.
We demonstrated using a murine model that plasma miRNA expression signatures could distinguish mice that received
total body irradiation doses of 0.5 Gy, 2 Gy, and 10 Gy (at 6 h or 24 h post radiation) with accuracy, sensitivity, and
specificity of above 90%. Taken together, these data demonstrate that plasma miRNA profiles can be highly predictive of
different levels of radiation exposure. Thus, plasma-based biomarkers can be used to assess radiation exposure after mass-
casualty incidents, and it may provide a valuable tool in developing and implementing effective countermeasures.
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Introduction
In the event of an improvised nuclear device attack or disaster in
a nuclear power plant, hundreds of thousands of people may be
exposed to various doses of radiation. Exposure to ionizing
radiation is associated with induction of acute radiation syndrome
(ARS), also known as radiation sickness, which is characterized by
nausea, vomiting, diarrhea, skin damage, and can include loss of
bone marrow, internal bleeding, and death. Depending on the
exposure dose, the symptoms of ARS can appear within hours to
weeks. The categories relevant to radiation exposure in popula-
tions have been defined [1]. Subjects receiving doses less than
2 Gy are asymptomatic or have mild symptoms; subjects receiving
doses from 2 to 6 Gy need immediate care, with variable survival
prognoses; and radiation doses .6 Gy will likely be lethal. At
doses .2 Gy, the hematopoietic system syndrome appears in
weeks to 2 months and mortality can occur within 1 month; at
doses of 8 Gy to 12 Gy, gastrointestinal effects occur within a week
after the exposure and death can occur within 10 days; at doses
.15 Gy, the central nervous system will be affected and fatalities
can occur within 2 days [2].
It is a challenge for medical responders to triage individuals who
are minimally exposed and do not need treatment compared to
those who received high dose radiation and need immediate
treatment [3]. The current strategy to assess individual radiation
exposure is based on symptoms developed over time. For example,
individual radiation dose is assessed by determining the time to
onset and severity of nausea and vomiting, lymphocyte depletion
kinetics, and cytogenetic analysis [1]. These methods are very
time-consuming and difficult to apply to an exposed population in
a real time scenario. In addition, the latent period (from radiation
exposure to symptom onset) is a critical time for therapeutic
intervention because many effective treatments such as antibiotics
or hematopoietic cytokines need to be administered before
radiation symptoms appear. Therefore, there is an urgent need
to develop biochemical or molecular biomarkers that can help in
implementing effective countermeasures of radiation injury to
affected individuals and provide basis for treatment decisions. The
levels of amylase, C-reactive protein, and other proteins have been
studied as radiation biomarkers [4]. However, the action of these
biomarkers can be affected by physiological conditions such as
inflammation or bacterial infection. c-H2AX foci at DNA double-
strand break sites in peripheral blood lymphocytes are also being
developed as biomarkers for determining the extent of radiation
exposure [5].
MicroRNAs (miRNAs) are small (typically about 22 nucleotide
in size) regulatory RNA molecules that modulate the activity of
specific mRNA targets and play an important role in many
biological processes. Circulating miRNAs (in plasma, serum or
other bodily fluids) are being assessed as biomarkers for various
pathological and physiological conditions. For example, circulat-
ing miRNAs are being investigated as stable, blood-based
biomarkers for prostate cancer, pancreatic cancer, acetamino-
phen-induced liver damage, and pregnancy [6,7,8]. There are
many advantages to using circulating miRNAs as biomarkers as
miRNA expression is frequently altered in diseases or during organ
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used in a high-throughput analysis with ease. High-throughput
miRNA expression analysis is extremely sensitive, rapid and
flexible PCR based assay and thus requires less effort compared to
traditional methods. The limitation of using plasma or serum
samples for miRNA analysis is that no specific miRNA is available
to use as an endogenous control to normalize the relative quantity
of miRNA in the plasma or serum. In contrast, house keeping
genes such as b-actin and GAPDH are commonly used in
quantitative RT-PCR analysis studying gene expression in various
tissues. Michell et al (2008) used synthetic Candida elegans miRNAs
as spiked-in controls [7]. Although this method is helpful to
normalize the variability in plasma or serum RNA extraction, it
cannot be used to normalize the variability in biological samples.
Using a murine model of single exposure total body irradiation
(TBI), we investigated whether circulating miRNA in plasma can
differentiate exposure to radiation doses of 2 Gy and higher and
developed a normalization strategy to analyze the data.
Materials and Methods
Animals and animal irradiation
All animal experimental protocols were in agreement with the
guidelines established by the institute and approved by the
Institutional Review Board at the Johns Hopkins University
Animal Care and Use Committee(Protocol No. MO08H274).
C57BL6 mice (male, 6–8 weeks old) were exposed to different
doses of gamma radiation (Total Body Irradiation, TBI) using a
GammaCell 40 irradiator with a Cesium-137 source (Atomic
Energy of Canada Limited) at a dose rate of 52 cGy/min. Control
mice were sham-exposed.
Blood collection and plasma preparation
Peripheral blood was collected after radiation by heart puncture
at 6 h or 24 h using BD Vacutainer K2 EDTA tubes (BD
Biosciences 367841). After collection of whole blood in BD
Vacutainer K2 EDTA tubes, these tubes were immediately and
gently inverted for 8–10 times. Plasma was processed within two
hours after blood collection. To harvest the cell-free plasma, we
used a two-step centrifugation method [9]. Blood samples were
first centrifuged at 2000 rpm for 10 min at room temperature
(according to BD Vacutainer instructions). The supernatant was
centrifuged again at 16000 g for 10 min at 4uC to remove residual
blood cells. Plasma samples were stored at 280uC. To test
whether there was residual platelet contamination in our plasma
samples, we quantified platelet counts using HemaVet H
HV950FS Multispecies Hematology Instrument (Drew Scientific,
Inc). Because platelet miRNAs from residual platelets or from
platelet lysis would show up in the plasma miRNA array, we
compared the platelet specific gene Itga2b in both plasma and
whole blood. 10% of plasma and 10% of buffy coat from the same
blood sample were used for RNA extraction. The ratio of Igta2b
between 10% of plasma and 10% buffy coat represents the ratio of
Itga2b between plasma and whole blood.
RNA extraction
RNA was extracted using mirVana PARIS kit (Ambion
AM1556). Because there is no suitable endogenous control for
plasma RNA, miR159a, a miRNA from Arabidopsis thaliana not
present in mammalian tissues, was added as a spiked-in control.
Mouse plasma (200 ml) was added to 205 ml2 6 denaturing
solution and mixed thoroughly. Synthetic miR159a (IDT, City
State) was then added to the mixture and mixed thoroughly. After
chloroform addition and phase separation, the aqueous layer was
mixed with 1.25 volumes of absolute ethanol. Then, the solution
was loaded onto the cartridge provided with the mirVana miRNA
isolation kit. The columns were washed according to the
manufacturer’s instructions, and the RNA was eluted in 50 ml
nuclease free H2O (95uC). To minimize DNA contamination, the
eluted RNA was treated with DNase I (Ambion AM1906).
microRNA profiling
Three microliters of total RNA was reverse transcribed using
the Megaplex
TM RT Primers Rodent Pool A and Pool B (Life
Technologies, Foster City, CA), enabling miRNA specific cDNA
synthesis. The resulting cDNAs were pre-amplified for 12 cycles
using the corresponding Megaplex
TM PreAmp Primers Rodent
Pool A or Pool B and TaqMan PreAmp Master Mix according to
the manufacturer’s protocol (Life Technologies, Foster City, CA).
The pre-amplified cDNAs were diluted 4 fold with 0.16TE
(pH 8.0). miRNA expression profiling was performed using
Taqman Rodent MicroRNA Array Card A and Card B (Applied
Biosystems) containing all 518 mature mouse miRNAs in miRBase
10.1 (http://microrna.sanger.ac.uk). PCR amplification and signal
detection was performed using the Applied Biosystems 7900HT
Fast RT-PCR System.
miRNA expression analysis
The miRNA expression results were analyzed using Real-Time
StatMiner software (Integromics, Madrid, Spain). miRNAs were
first normalized using global mean normalization across all miRNA
TaqMan arrays to achieve the same mean Ct (determined using
only miRNAs passing detection threshold (Ct,32) for each array).
To minimize potential noise introduced by measurements below
detection threshold, miRNAs withCt.35 in all groups werefiltered
out. miRNAs that were differentially expressed for each of the three
radiationdosesafter 6 hrand 24 hr were identified using a LIMMA
modified t-test (p,0.05). Hierarchical clustering (Pearson’s Dissim-
ilarity algorithm) was performed using Partek Genomic Suite
(Partek Inc., St Louis, MO, USA). Average-linkage hierarchical
clustering analysis and visualization was performed using the
CLUSTER and TREEVIEW programs, respectively, (software
available at http://genome-www5.stanford.edu/resources/restech.
shtml).
Construction and validation of miRNA-based prediction
models for radiation doses
A 40-sample training set containing 10 samples for each
radiation dose collected from mice (n=10/group) exposed to 0,
0.5, 2.0, and 10 Gy at 6 h and 24 h was used to select classifier
miRNAs and construct a prediction model. To establish the
prediction models for radiation doses, Ct values of a low
abundance miRNA with Ct values equal or above 32 in all
groups were replaced with a Ct value of 32 to perform stricter
statistical analysis. miRNA-based prediction models for radiation
doses were constructed and validated by prediction analysis of
microarrays, using a statistical package (http://www-stat.stanford.
edu/,tibs/PAM/) that applies nearest shrunken centroid analysis
and cross-validation to determine the minimal set of predictor
genes that achieve optimal prediction accuracy for sample
classification [10]. The optimal number of classifier genes was
determined by choosing an optimal threshold with 0% training
error. For validation of the prediction models, a 10-fold cross
validation was performed on the training set. The 40 training
samples were partitioned into 10 bins, with equal representation of
radiation doses similar to the initial set of samples. Nine bins were
used for standardization purposes to construct the prediction
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remaining bin was predicted. Classification errors were calculated
for each dose to evaluate the performance of each prediction
model.
Results
Survival of mice after exposure to different doses of
radiation
First, we studied the survival of mice receiving 0.5, 2, and 10 Gy
TBI. C57BL6 mice (6–8 weeks old, male, n=10 per group) were
exposed to a single dose of 0.5, 2, or 10 Gy TBI from a Cs137
gamma source at a dose rate of 52 cGy/min. The survival results
are shown in Figure 1A. We confirmed that 10 Gy TBI was lethal
and resulted in 100% mortality within 2 weeks; while there was no
mortality at a dose of 2 Gy or lower in 30 days.
Establishment of spiked-in controls
We established the linear range of spike-in miRNA in mouse
plasma. Different quantities of miR159a were spiked into 200 ml
plasma of untreated C57BL6 mice. RNA from the plasma was
extracted and reverse transcribed, and RT-PCR was performed to
detect the spiked-in miRNA levels. As shown in Figure 1B&C,
spiked miR159a in the range of 3000 pg to 0.03 pg (serial 10-fold
dilutions) was detected in the linear range in both Pool A and B of
the Taqman assay. The yield from this titration produced an
excellent linear regression correlation (R2=0.967 and R2=0.995,
respectively) suggesting that miR159a can function as an optimal
spiked-in control. For later experiments, we chose to spike-in
30 pg of miR159a to 200 ml of plasma sample.
Experimental design
The experimental design is shown in Figure 1D. To study the
plasma miRNA expression alteration due to different radiation
doses, C57BL6 mice were exposed to the same three doses of TBI
as shown in Figure 1A. These three doses were chosen because
each dose represents an exposure with different pathophysiological
implications. Blood was drawn at 6 h and 24 h after radiation and
plasma was prepared and stored at 280uC. Plasma miRNA was
extracted and used for miRNA Taqman array. Microarray
analyses were performed as described in the Materials and
Methods.
Normalization strategies
Current approaches to normalize the circulating miRNAs
include the use of established endogenous miRNAs, spiked-in
miRNAs or global mean of miRNAs. To select the best method to
normalize the miRNA expression level, we tested normalization
based on mammalian U6, spiked-in miR159a, or global mean of
miRNAs with Ct,32. First, we normalized the expression value
using mammalian U6, which is widely used as an endogenous
control for tissue or cell miRNA normalization. As shown in
Figure 1E, miRNA expression levels normalized using mammalian
U6 showed high variation within individual treatment groups.
Normalization based on spiked-in miR159a showed less variation
within each group compared to the normalization based on U6
(Figure 1F). Normalization based on the global mean of each plate
showed even better results within each group compared to
normalization based on miR159a as a normalizer (Figure 1G).
Since the global mean expression value is the best ranked
normalization factor, which significantly reduces technical varia-
tion, we chose to normalize the expression values based on global
mean of miRNAs.
Contamination from platelets
Because platelets are the most easily lysed cells during plasma
preparation and it has been shown that platelets contain miRNAs
[11], there is a possibility of platelet miRNA contamination of
plasma miRNAs. Platelets have been shown to be extremely
resistant to radiation. Radiation doses as high as 75000 rads (which
equals to 750 Gy) caused no damage to platelets [12]. Platelet
miRNA might contaminate plasma miRNA in two ways. Firstly,
there might be residual platelets in the plasma after centrifugation.
Secondly, platelets might be lysed during the preparation of plasma
and release platelets miRNAs into the plasma. To establish whether
there was platelet contamination, and if there was, whether the
contamination was similar in different samples, we did three
experiments. Firstly, we quantified the residual platelets in plasma
after centrifugation. As shown in Figure S1B, there were
583.4644.4 k/ml platelets in the whole blood. After first centrifu-
gation, there were 13.062.3 k/ml platelets remaining in the plasma.
After the second centrifugation, there were only 4.860.3 k/ul
platelets remaining in the plasma. Therefore, we removed 97.8%
platelets after first centrifugation and 99.2% platelets after second
centrifugation. Because platelet counts after second centrifugation
was in the lowest linear range of HemaVet machine we used (the
linear range is 1 to 4000 k/ml), we believe that the removal of
platelets from plasma was very efficient. Secondly, we did realtime
PCR to measure the platelet specific gene product Itga2b (also
called glycoprotein IIb, GPIIb) in the whole blood and plasma.
Realtime PCR result showed that Itga2b expression was dramat-
ically decreased in the plasma compared to the whole blood. The
arbitrary Ct values of whole blood Igta2b was 1660.45, the
arbitrary Ct values of plasma Igta2b after first centrifuge was
3260.21 and the arbitrary Ct values of plasma igta2b after second
centrifuge was 3660.53 (based on the line draw). Based on the delta
delta CT method to calculate the fold change in gene expression in
plasma and whole blood, the fold decrease from whole blood to
plasma after first centrifuge was 55521 and to plasma after second
centrifuge was decreased to 1454803 folds (as shown in Figure S1A
and S1C). This also suggests that even if there were platelet miRNA
contaminations, the level of contamination was very low. The Ct
values of Itga2b in plasma samples had a normal distribution,
suggesting that even if there were platelet lysis during plasma
preparation, the contamination would not vary much in different
samples. Thirdly, we compared the most abundant miRNAs from
platelets and plasma. Since plasma miRNA levels are very low, tiny
contamination from platelet might affect the constituent of plasma
miRNA. We studied the distribution of the 10 most abundant
platelet miRNAs in plasma and the distribution of the 10 most
abundant plasma miRNAs in platelets. Because there is no miRNA
data from mouse platelets and miRNAs are known to be much
conserved between species, we believe it is acceptable to use the
miRNA data from human platelets to compare with mousesamples.
We used the human platelet miRNAs abundance list from Landry P
et al [11]. We showed the comparison in Figure S1D and S1E. We
showed that the 10 most abundant platelet miRNAs ranked from
the13thmostabundantto227thmostabundantinplasma miRNAs
(Figure S1D). The 10 most abundant plasma miRNAs ranked from
12th to 150th in the platelet, and three of the mostabundant plasma
miRNAs were absent from the platelet list (Figure S1E). Our results
suggestthattherewerenegligibleplateletmiRNAcontaminationsof
our plasma samples.
Differential expression of plasma miRNA after ionizing
radiation
To identify a miRNA expression signature in the plasma in
response to ionizing radiation, miRNA profiles of plasma samples
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and 10 Gy, n=10/dose) were analyzed using TaqMan Rodent
MicroRNA Array Card A and Card B containing 518 mature
mouse miRNAs. A set of 239-miRNA and 182-miRNA signature
was determined at 6 h and 24 h post radiation exposure,
respectively. As shown in Figure 2 A&B, hierarchical clustering
Figure 1. Experimental design and scheme for development of radiation response expression signature. A: C57BL6 mice survival after
TBI. C57BL6 mice (male, 6–8 weeks old) were irradiated with 0 Gy, 0.5 Gy, 2 Gy and 10 Gy TBI. Animal survival was monitored for 30 days (N=10 in
each group). B&C :The linear range of spiked-in miRNA control. miR159a from 0.03 pg to 3000 pg (in 10 fold increase) showed a linear reaction in
both Array A and Array B reactions. X axis: log of spiked-in miRNA control (in picogram); Y axis: Ct values detected using real time PCR. D:
Experimental design for development of radiation response signature. Plasma was collected from 0 (control), 0.5-, 2-, and 10 Gy-irradiated C57BL6
mice at 6 h and 24 h after exposure. miRNA array analyses were performed on the RNA isolated from n=10 replicates from each condition, and
metagene profiles were developed to represent 4 different levels of radiation exposure at 2 time points. For the metagene profiles, a 10-fold cross
validation was performed, which revealed the highly predictive nature of these metagene profiles. E–G: showed the box plot distribution of
normalized Ct values in each sample using three different normalization methods. E: Ct distribution after normalization using mammalian U6 as the
normalizer; F: Ct distribution after normalization using spiked-in miR159a as the normalizer; G: Ct distribution after normalization using the global
mean as the normalizer. The yellow boxes represent the first quartile (Q1) and third quartile (Q3) of Ct values in each sample, while the whisker bars
represent the upper and lower adjacent values of Cts in each sample. Blue triangles represent median Ct values and black triangles represent mean Ct
values.
doi:10.1371/journal.pone.0022988.g001
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miRNA expression and clearly distinguished the non-irradiated
samples from the irradiated samples. Furthermore, it is evident
that clusters of miRNAs could discretely separate the samples as a
function of radiation dose. These results suggest that there was
alteration in the expression of a specific set of miRNAs in mice
blood after exposure to various doses of radiation.
Dose-dependent differential expression of miRNA
Given the pattern of plasma miRNA expression after exposure
to radiation, we identified the miRNAs that have a distinct
expression at specific doses and time points (clustered using
Pearson’s dissimilarity as distance measure). There were 23, 32,
and 39 unique miRNAs (metagenes) that significantly changed
after exposure to 0.5, 2, and 10 Gy ionizing radiation at 6 h,
respectively (Figure 3A–C). We also analyzed miRNAs that were
differentially expressed in response to different doses of radiation
at 24 h. There were 40, 49, and 27 unique miRNAs that were
significantly altered after exposure to 0.5, 2, and 10 Gy ionizing
radiation at 24 h, respectively (Figure 4A–C). As shown in
Figure 3D, there were 35 miRNAs that were significantly changed
after exposure to all three doses of radiation (0.5, 2 and 10 Gy) at
6 h compared to unirradiated samples. Nine miRNAs were
significantly changed after exposure to all three doses of radiation
Figure 2. Different doses of ionizing radiation affect plasma miRNA expression profiles. A: Hierarchical clustering of 40 samples (10
controls and 10 samples from each of the following radiation doses 0.5 Gy, 2 Gy and 10 Gy at 6 h) using 239 differentially expressed miRNAs
(p,0.05). B: Hierarchical clustering of 40 samples (10 controls and 10 samples from each of the following radiation doses 0.5 Gy, 2 Gy and 10 Gy at
24 h) using 182 differentially expressed miRNAs (p,0.05). The level of expression of each gene in each sample is represented using a red-black-green
color scale as shown in the key (high expression is depicted as red, and low expression is depicted as green, unchanged expression is depicted as
black). The radiation level of each sample is color coded as illustrated.
doi:10.1371/journal.pone.0022988.g002
Figure 3. Differential expression of plasma miRNA after different radiation doses at 6 h. The heatmap depicts the expression pattern of
miRNAs showing significantly differential expression compared to control group. miRNAs that were significantly changed compared to the control
group and uniquely expressed in 0.5 Gy,2 Gy and 10 Gy radiation dose were shown in A to C. A: 23 miRNAs that were uniquely changed in the
0.5 Gy 6 h group compared to the control group. B: 32 miRNAs that were uniquely changed in the 2 Gy 6 h group compared to the control group. C:
39 miRNAs that were uniquely changed in the 10 Gy 6 h group compared to the control group. D: 27 miRNAs that were significantly changed in all
three irradiation groups compared to the control group. High expression is depicted as red, and low expression is depicted as green, unchanged
expression is depicted as black.
doi:10.1371/journal.pone.0022988.g003
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(Figure 4D). We found that the differential expression of miRNAs
after radiation exposure was specific to radiation doses. These data
suggest that radiation exposure induces dose-dependent changes in
plasma miRNA expression.
Temporal expression of plasma miRNA after radiation
We found a temporal relationship between the expression of
miRNAs and radiation by comparing the miRNAs from the same
dose to different time points (Figure 3&4). As shown in Figure 5,
there were 23 and 40 miRNAs that were uniquely differentially
expressed at 0.5 Gy for 6 h and 24 h, respectively. Among them,
only one was common at both time points. Similarly, there were
32 and 49 miRNAs that were uniquely differentially expressed at
2 Gy for 6 h and 24 h, respectively. Of these, only 1 miRNA was
differentially expressed at both time points. There were 39 and 27
miRNAs that were uniquely and differentially expressed at 10 Gy
for 6 h and 24 h, respectively. Of these, only 2 miRNA were
differentially expressed at both time points. This suggests that the
expression of plasma miRNA after exposure to radiation is a
dynamic process.
Development of radiation response signature that can
predict radiation doses
Since we were able to develop a miRNA signature reflective of
radiation dosage, we attempted to find the expression signatures or
metagenes that could accurately predict the exposure to various
doses of radiation. We used the PAM statistical package to
determine the minimal sets of miRNAs that can predict specific
radiation doses at 6 h and 24 h. As shown in Figure 6A, while
training the 6 h time point samples, a 32 miRNA model was
identified; and its training error was 0% (Figure 6B). To cross
validate the model, we used a 10-fold cross validation. As shown in
Figure 6C, the 32 miRNA metagene can distinguish all radiation
Figure 4. Differential expression of plasma miRNA after different radiation doses at 24 h. The heatmap depicts the expression pattern of
miRNAs showing significantly differential expression compared to the control group. miRNAs that were significantly changed compared to the
control group and uniquely expressed in one radiation dose are shown in A to C. A: 40 miRNAs that were uniquely changed in the 0.5 Gy 24 h group
compared to the control group. B: 49 miRNAs that were uniquely changed in the 2 Gy 24 h group compared to the control group. C:27 miRNAs that
were uniquely changed in the 10 Gy 24 h group compared to the control group. D: 9 miRNAs that were significantly changed in all three irradiation
groups compared to the control group. High expression is depicted as red, and low expression is depicted as green, black means no change.
doi:10.1371/journal.pone.0022988.g004
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was 0% for the unirradiated and 10 Gy 6 h comparison and 10%
for the 0.5 Gy 6 h and 2 Gy 6 h groups. A heatmap of these 32
miRNAs is shown in Figure 6E. The overall accuracy, sensitivity,
and specificity of the 32 miRNA signature for the 6 h group are
shown in Table 1. The 32 miRNA signature achieved 97.5%
overall accuracy in the 6 h groups; 100% sensitivity in the
unirradiated and 10 Gy groups; 90% sensitivity in the 0.5 Gy and
2 Gy groups; and 97% specificity in the unirradiated and 10 Gy
groups; and 100% specificity in the 0.5 Gy and 2 Gy groups.
In addition, we performed the training on the 24 h samples and
found a 12 miRNA model that could distinguish all four radiation
doses with 0% training error (Figure 7A&B). As shown in
Figure 7C, the 12 miRNA model could distinguish 0, 0.5, 2,
and 10 Gy. The predictive error was 10% for the 0 Gy and
0.5 Gy group at 24 h and 0% for all other groups. Figure 6E
shows the heatmap of the 12 miRNAs that could distinguish the
specific radiation doses at 24 h. As shown in Table 1, at 24 h, the
12 miRNA signature achieved 97.5% overall accuracy in the
unirradiated and 0.5 Gy groups; 100% overall accuracy in the 2
and 10 Gy group comparison; 100% sensitivity in the unirradiated
group and 2 and 10 Gy groups; 90% sensitivity in the 0.5 Gy
group; 97% specificity in the unirradiated group; and 100%
specificity in the 0.5, 2 and 10 Gy groups.
Discussion
In the case of a nuclear disaster or nuclear device attack, a triage
diagnostic screening approach will be very useful to rapidly and
accurately determine the severely radiation-exposed individuals
from those who were exposed to sublethal dose (,2 Gy).
Molecular biodosimetry tools can be extremely valuable assets
for medical triage and patient management and implementation of
effective countermeasures. Many studies have demonstrated that
after radiation exposure, interventions aimed at ameliorating the
effects of radiation must be applied early. Delayed administration
of countermeasures is not effective. Because many symptoms of
ARS are delayed, it is important to use predictive biomarkers that
can distinguish the level of radiation exposure. Traditional
methods such as lymphocyte depletion or cytogenetic analysis
[1] are very time consuming and labor intensive. Gene-expression
or molecular biomarkers are being tested to detect radiation
exposure for prompt and effective implementation of counter-
measures.
We chose the three radiation doses (0.5 Gy, 2 Gy and 10 Gy)
because each radiation dose has its own medical significance. It is
well established that 0.5 Gy exposure causes no acute health
effects, whereas 2 Gy is myelosuppressive and immunosuppressive
and 10 Gy is in upper range of survival with supportive care and
cytokines. In a scenario following a large nuclear event, it is critical
to identify those individuals who will benefit from medical
intervention at an early stage. But it is also crucial to exclude
and reassure patients who do not need medical intervention since
the medical resources will be extremely limited. People receiving
radiation doses from 2 Gy to 10 Gy need immediate medical
attention. The best estimate for the LD50/50 in humans is in the
3.5 to 4.5 Gy range, however, this value can be roughly doubled
through the use of antibiotics, platelet and cytokine treatment [13].
In the dose of approximately 7–10 Gy, bone-marrow transplan-
tation is a useful option (above 10 Gy is usually lethal because of
lethal gastrointestinal damage) [14]. Therefore, we believe a
biomarker to distinguish 2 Gy and 10 Gy is utmost important
because people receiving these doses all need medical attention. In
fact, researchers have used these three radiation doses for
biomarker studies [15,16,17]. Further studies using other radiation
doses such as 4 Gy or 6 Gy will give us a better understanding of
the plasma miRNAs after radiation exposure.
The type of anticoagulant used in plasma collection tubes is very
important to consider. Spray-dried EDTA is the preferred
anticoagulant for quantitative molecular diagnostic tests. Collect-
ing plasma using heparin will interfere with PCR reaction because
heparin will bind to the calcium and magnesium present in the
master mix for PCR reactions; citrate will dilute plasma and can
cause hemolysis( http://www.bd.com/vacutainer/faqs/). To get
cell-free plasma, we used a two-step centrifugation method, which
has been shown to be effective in producing cell-free plasma [9].
Platelets are stable in EDTA-anticoagulated blood for 24 hrs [18].
Our blood samples were processed within 2 hours after blood
draw. Also we showed that there was minimal platelet lysis
contamination by measuring the Itga2b levels. At least 99.2% of
platelets were removed from plasma after the second centrifuga-
tion. Furthermore, we showed that there was almost no platelet
specific gene itga2b in the plasma after the second centrifugation.
The expression level of itga2b was around 1.56106 fold lower
than that in the whole blood. The most convincing results are from
the comparison of the most abundant miRNAs from platelets and
plasma. If there was significant miRNA contamination from
platelets, the 10 most abundant platelet miRNAs should rank very
high and closely in plasma samples. Also if there was significant
contamination from platelets, the 10 most abundant plasma
miRNAs should rank very high in the platelet list. The fact that the
first three most abundant plasma miRNAs were not detected in
the platelet samples suggests that platelets are not a major source
of plasma miRNAs. In summary, our results suggest that there
were negligible platelet miRNA contaminations of our plasma
samples.
There is a strong rationale to develop non-invasive biomarkers
reflective of radiation exposure based on molecular changes such
as DNA, RNA and plasma protein [17,19,20]. The expression of
mRNA isolated from mononuclear cells has been used to predict
radiation doses; however, mRNA is intrinsically unstable [21]. A
protein-based approach provides an alternative and complemen-
tary approach to microarray technology for the identification and
validation of proteins. However, there are concerns associated
Figure 5. Venn diagram showing the time-dependent expres-
sion of miRNAs. Significantly changed miRNAs at the same dose but
different time points were used for drawing the Venn diagram. The
miRNA lists were from Figure 3 A to C and Figure 4 A to C. miRNAs that
were uniquely changed at 6 h were colored in lime green. miRNAs that
were uniquely changed at 24 h were colored in blue. miRNAs that were
changed at both 6 h and 24 h were colored in red.
doi:10.1371/journal.pone.0022988.g005
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compositions, posttranslational modifications, low abundance of
proteins of interest, and difficulty in developing detection
methods with high affinity [22,23]. Plasma B1 DNA seems to
be a simple and accurate biomarker for detecting radiation
exposure in biological systems [20]; however, it is known that
plasma DNA levels can increase as a result of many illnesses
[24,25,26]. Unlike mRNA-based biomarkers, miRNA based
biomarkers are relatively stable and their total number is small.
The measurement of miRNAs in plasma has the advantage of
reduced noise compared to measurements of mRNA from blood
cells, which can have variation due to differences in the cell
number due to infection and other secondary conditions
unrelated to exposure. However, one advantage to using mRNA
as a biomarker instead of miRNA is the presence of well-
established internal controls in mRNA samples.
Figure 6. miRNA expression profiles that distinguish different levels of radiation exposure at 6 h. A: Determination of the optimal set of
32 predictor miRNAs and threshold with minimal (0%) training error. B: The confusion matrix table showed the individual training error for each class.
C: 10-fold cross validation of the 32-predictor model on the training set (see detailed description in Methods). Probability of being predicted as
normal or each individual radiation dose was plotted for each sample. The radiation level of each sample is color coded as illustrated (red, 0 Gy;
green, 0.5 Gy; blue, 2 Gy; orange, 10 Gy). D: The confusion matrix table showed the individual cross validation error for each class. E:hierarchical
clustering of the 32-miRNA in prediction model for radiation doses at 6 h. High expression is depicted as red, and low expression is depicted as green,
unchanged expression is depicted as black.
doi:10.1371/journal.pone.0022988.g006
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miRNA data. We have demonstrated that global normalization
across the samples is the optimal choice. Our data show that
gamma radiation causes quantifiable and reproducible miRNA
gene expression changes in plasma in a time- and dose-dependent
manner. miRNA expression profile can predict and distinguish the
level of radiation exposure in mice, ranging from 0.5 Gy to 10 Gy.
The 32 miRNA metagene profile at 6 h demonstrated 97.5%
accuracy in distinguishing non-irradiated mice from those exposed
to 0.5, 2, or 10 Gy. The 12 miRNA metagene profile at 24 h post
radiation demonstrated at least 97.5% accuracy in distinguishing
non-irradiated mice from those exposed to 0.5, 2, or 10 Gy.
Combined with other discrimination indices of radiation exposure,
we showed that this miRNA profiling method can help to
effectively predict radiation casualty incidents.
We found about 50% of all the known miRNAs in the plasma.
The high abundance of many circulating miRNAs in the plasma
suggests they might have potential biological roles. Among the
miRNAs in the plasma, many have been shown to have
differential expression in cells or tissue after ionizing radiation,
such as miR-142-5p [27], miR-339, hsa-miR-342, hsa-miR146a,
hsa-miR-29c, hsa-miR155, hsa-miR-197, hsa-miR-34b [28], and
miR-29c [29]. We also found that miR34a was elevated in all
plasma samples exposed to radiation. miR34a has been shown to
be up-regulated after ionizing radiation both in vitro and in vivo
[30]. After exposure to gamma radiation, p53 is activated through
ATM-kinase and transactivates the expression of different
members of the miR34 family through consensus binding sites.
miR34 genes are then processed by DROSHA and DICER
complexes. The mature miR-34 incorporates in the RISC
complex and mediates the inhibition of translation or RNA
degradation of their targets, such as Bcl-2 and Cyclin D1 [31]. The
activation of p53 increases the levels of the miR34 family, which
are direct targets of p53. The activation of the miR34 family then
regulates their target proteins such as CDK4 and Rb to regulate
the cell cycle. Circulating miRNAs might act as extracellular
messengers mediating short- and long-range cell-cell communica-
tion similar to roles played by small RNAs in C. elegans and plants
[32,33]. Further studies are needed to explore the potential
biological roles of circulating miRNAs.
Radiation at doses from 2 Gy to 10 Gy causes damage mainly
to the bone marrow and GI tract. We expect that these two
radiosenstive organs might release miRNAs to the plasma after
radiation exposure. Currently there are limited studies about the
tissue specific or tissue enriched miRNAs. miR125a and miR125b
have been shown to be enriched in bone marrow [34] and there
are about 30 miRNAs shown to be enriched in the small intestine
compared to liver [35]. Among them, only miR-142-5p showed up
in our 6 h metagene and none showed up in our 24 h metagene.
We studied the tissue distribution of the 32 and 12 miRNAs we
found in the 6 h and 24 h metagenes respectively by searching two
miRNA databases. The two databases are MicroRNAdb (http://
bioinfo.au.tsinghua.edu.cn/micrornadb/) and miRNAMap ( http:
//mirnamap.mbc.nctu.edu.tw/). Searching other databases, such
as CoGemiR and miRBase, returned no information about the
tissue distribution of our interested miRNAs. We found that some
of our miRNAs are reported to be enriched in bone marrow (miR-
142) and GI tract (miR-142, miR-150, miR-155). miR142 is
highly expressed in the hemotopoietic organs such as bone
marrow, spleen and thymus [36]. miR142 is also shown to have 1
clone in small intestine and 6 clones in colon. miR-150 has one
clone in colon [37]. miR-155 has one clone in colon [37,38]. The
remaining miRNAs in our metagenes are either having a tissue
origin from other tissues or without tissue origin information.
However, as shown by Wang et al [39], the composition of
circulating miRNAs might originate from diverse tissues and cell
types in the body after acetaminophen-induced liver damage. It is
not surprising if our miRNAs are released from tissues other than
bone marrow and GI. Whether these miRNAs are released from
the radiation target organs warrants further study.
Differentially expressed plasma miRNAs have been studied in
many models. Plasma miR150 has been shown to be up-regulated
after LPS treatment [40]; plasma miR-122 level has been shown to
be increased by viral-, alcohol-, and chemical-related hepatic
diseases [41]. Plasma miR208b and miR449 have been shown to
be highly elevated by cardivascular damage [42]. Plasma miR-22,
miR-101b, miR-122, miR -133a, miR135a*, miR-192, miR193 and
miR486 have been shown to be affected by liver damage [39]. None
of these differentially expressed plasma miRNAs showed up in our
radiation metagenes. This suggests that our metagene is very specific
for radiation injury. Our findings also strengthen the argument that
certain plasma miRNAs are biomarkers for different diseases.
The mechanisms of how circulating miRNAs are released into
circulation are not clear. One possibility is that cells are actively
secreting vesicles or exosomes that contain miRNAs [43,44].
Another possibility is that a ceramide dependent pathway controls
the intercellular transfer of miRNAs via exosome [45]. Other
research suggested that apoptotic cells release miRNAs via apoptotic
body [46]. One recent study suggested that circuilating miRNAs are
released by cells via Argonaut2 protein complexes [47]. A recent
study also showed that released miRNAs do not necessarily reflect
the abundance of miRNA in the cell of origin [48]. The releasing of
miRNA to the circulation might not be a simple trash disposal
mechanism [49], rather it may be a well controlled process.
Studieshaveshownthat plasmamiRNAsarestablein plasmaafter
24 hours’ incubation at room temperature, or undergoing eight
cycles of freeze-thawing [7]. The protective exsosomes, microvesicles
and Argonaute2 protein complexes are responsible for the stability of
plasma miRNAs [50,51] [47]. Whether plasma miRNAs need to be
Table 1. Prediction of radiation doses with PAM using the 32-
miRNA expression signature and the 12-miRNA expression
signature for 6 h and 24 h, respectively.
Treatment
Overall Accuracy
a
(%)
Sensitivity
b
(%)
Specificity
c
(%)
6 h Post TBI
0 Gy 97.5 100 97.0
0.5 Gy 6 h 97.5 90.0 100
2 Gy 6 h 97.5 90.0 100
10 Gy 6 h 97.5 100 97.0
24 h Post TBI
0 Gy 97.5 100 97.0
0.5 Gy 24 h 97.5 90.0 100
2 Gy 24 h 100 100 100
10 Gy 24 h 100 100 100
PAM: statistical package, Prediction Analysis of Microarrays.
aPrediction accuracy was determined by 10-fold cross-validation on the 40
samples receiving different doses of radiation. Accuracy=(the number of
samples predicted correctly)/(total number of samples analyzed).
bSensitivity=(the number of positive samples predicted)/(the number of true
positives).
cSpecificity=(the number of negative samples predicted)/(the number of true
negatives).
doi:10.1371/journal.pone.0022988.t001
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complexes before their degradation needs further studies.
In summary, our study describes a rapid screening test for the
molecular dosimetry of radiation exposure. Further validation
studies are required before these miRNA targets can be used for
molecular biodosimetry to predict the radiation exposure. Studies
are underway to validate miRNA profiling method in patients or
monkeyswhoundergoTBI. Oncevalidated, the miRNAexpression
signatures would provide an early dose estimate that would then be
used when making decisions to triage patients. To our knowledge,
this is the first report of use of plasma miRNA as radiation exposure
biomarkers. This study provides proof-of-principle to the use of
plasma miRNA as a predictive tool for radiation exposures.
Supporting Information
Figure S1 Detection of possible platelet contamination
in plasma. A: The amplification plot of platelet specific gene itga2b
in the whole blood and plasma after first and second spins detected by
realtime PCR. The arbitrary threshold was shown in a blue line. B:
Platelet counts in whole blood and plasma using HemaVet machine.
C: The fold changes of itga2b gene in whole blood, after first and
second spins based on the Ct value measured in Figure S1A. D: The
ranking in the plasma of the 10 most abundant platelet microRNAs.
E: The ranking in the platelet of the 10 most abundant plasma
microRNAs. N/A means these miRNAs were not detected in platelet.
(TIF)
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